Co-Authors
This is a "connection" page, showing publications co-authored by KEN HE YOUNG and YONG LI.
Connection Strength
4.229
-
EBV-positive DLBCL frequently harbors somatic mutations associated with clonal hematopoiesis of indeterminate potential. Blood Adv. 2023 04 11; 7(7):1308-1311.
Score: 0.893
-
Remodeling of anti-tumor immunity with antibodies targeting a p53 mutant. J Hematol Oncol. 2024 06 18; 17(1):45.
Score: 0.242
-
Tumor-Infiltrating Normal B Cells Revealed by Immunoglobulin Repertoire Clonotype Analysis Are Highly Prognostic and Crucial for Antitumor Immune Responses in DLBCL. Clin Cancer Res. 2023 12 01; 29(23):4808-4821.
Score: 0.233
-
AI-powered discovery of a novel p53-Y220C reactivator. Front Oncol. 2023; 13:1229696.
Score: 0.228
-
PD-L1 translocation to the plasma membrane enables tumor immune evasion through MIB2 ubiquitination. J Clin Invest. 2023 02 01; 133(3).
Score: 0.220
-
Expanding anti-CD38 immunotherapy for lymphoid malignancies. J Exp Clin Cancer Res. 2022 Jun 28; 41(1):210.
Score: 0.211
-
Posttranslational Modifications in PD-L1 Turnover and Function: From Cradle to Grave. Biomedicines. 2021 Nov 16; 9(11).
Score: 0.203
-
Clinical and Immunological Effects of p53-Targeting Vaccines. Front Cell Dev Biol. 2021; 9:762796.
Score: 0.202
-
MYD88 L265P elicits mutation-specific ubiquitination to drive NF-?B activation and lymphomagenesis. Blood. 2021 03 25; 137(12):1615-1627.
Score: 0.194
-
Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenstr?m macroglobulinemia. Neoplasia. 2021 04; 23(4):361-374.
Score: 0.193
-
Targeting PD-L1 in non-small cell lung cancer using CAR T cells. Oncogenesis. 2020 Aug 13; 9(8):72.
Score: 0.186
-
Mutant p53 as an Antigen in Cancer Immunotherapy. Int J Mol Sci. 2020 Jun 08; 21(11).
Score: 0.183
-
Ubiquitination of the DNA-damage checkpoint kinase CHK1 by TRAF4 is required for CHK1 activation. J Hematol Oncol. 2020 05 01; 13(1):40.
Score: 0.182
-
Tissue-specific microRNA expression alters cancer susceptibility conferred by a TP53 noncoding variant. Nat Commun. 2019 11 07; 10(1):5061.
Score: 0.176
-
Genetic alterations and their clinical implications in DLBCL. Nat Rev Clin Oncol. 2019 10; 16(10):634-652.
Score: 0.175
-
Glyphosate induces benign monoclonal gammopathy and promotes multiple myeloma progression in mice. J Hematol Oncol. 2019 07 05; 12(1):70.
Score: 0.172
-
Genetic Subtyping and Phenotypic Characterization of the Immune Microenvironment and MYC/BCL2 Double Expression Reveal Heterogeneity in Diffuse Large B-cell Lymphoma. Clin Cancer Res. 2022 Mar 01; 28(5):972-983.
Score: 0.052
-
Determining clinical course of diffuse large B-cell lymphoma using targeted transcriptome and machine learning algorithms. Blood Cancer J. 2022 02 01; 12(2):25.
Score: 0.051
-
Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents. Mol Cancer Res. 2021 02; 19(2):249-260.
Score: 0.047
-
XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53. J Hematol Oncol. 2020 11 04; 13(1):148.
Score: 0.047
-
A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCL. Blood Adv. 2020 07 28; 4(14):3391-3404.
Score: 0.046
-
Prognostic factors, therapeutic approaches, and distinct immunobiologic features in patients with primary mediastinal large B-cell lymphoma on long-term follow-up. Blood Cancer J. 2020 05 04; 10(5):49.
Score: 0.046
-
Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies. J Immunother Cancer. 2019 10 22; 7(1):272.
Score: 0.044